Navigation Links
Oncos Therapeutics Granted Orphan Drug Designation for CGTG-102 in Soft Tissue Sarcoma (STS) by FDA and EMA
Date:7/31/2013

HELSINKI, Finland, July 31, 2013 /PRNewswire/ --

Oncos Therapeutics Ltd, a private, clinical-stage biotechnology company focused on the development and commercialization of targeted oncolytic immunotherapies for solid tumors, announced today that the United States Food and Drug Administration (FDA) and European Medicines Agency (EMA) have granted orphan drug designation for CGTG-102, a granulocyte-macrophage colony stimulating factor-coding oncolytic adenovirus (Ad5/3-D24-GMCSF) for the treatment of soft tissue sarcoma.

     (Logo: http://photos.prnewswire.com/prnh/20130731/630919)

"We are pleased to receive orphan drug designations for CGTG-102 from the two leading regulatory agencies in the world. These designations confirm the need for developing novel therapies for rare cancers and are an important step in the development of CGTG-102" ,said Frans Wuite, M.D., President and Chief Executive Officer of Oncos.

Orphan Drug Designation applies to drugs that seek to treat rare diseases or conditions for which there may be few adequate therapies. In USA, the designation will provide Oncos with the opportunity of seven years of marketing exclusivity, grant funding to defray costs of clinical trial expenses, tax credits for clinical research expenses and potential waiver of the FDA's application user fee. Similarly, incentives are provided for Europe by EMA, which include fee reductions on future activities and the potential for 10 years market exclusivity.

About Soft Tissue Sarcoma

Soft tissue sarcoma is estimated to affect 3-4 in 10,000 people in the EU and US. About 50% of soft tissue sarcomas are found in the early stage and advanced stage patients have an average overall survival of 13 months with today's standard of care. Several efforts to develop additional chemotherapeutics for STS have failed, including two products in Phase III development this year. Novel therapies with a different mechanism of action are therefore needed.

About CGTG-102

Oncos' lead product candidate, CGTG-102, is an oncolytic immunotherapy based on a purposefully modified, GM-CSF encoding adenovirus that selectively replicates in tumor cells and eventually kills them. Upon tumor cell death, newly synthesized viruses are released and infect neighboring tumor cells. Simultaneously, tumor antigens are exposed activating a tumor specific, systemic response by the patient's immune system. This response is further enhanced by the CGTG-102 induced production of GM-CSF in tumor cells.
A Phase I study with CGTG-102, will be completed this year and Phase II studies are scheduled to start in 2014. Prior to the Phase I study, 115 patients with chemotherapy refractory solid tumors had been treated with CGTG-102 in an individualized treatment program regulated by the Finnish Medicines Agency as determined by the EU Regulation on Advanced Therapy Medicinal Products, EC/1394/2007.

About Oncos Therapeutics

Oncos Therapeutics Ltd is a privately owned, clinical-stage biotechnology company focused on the development and commercialization of targeted oncolytic immunotherapy products for solid tumors. The company's lead investor is HealthCap, one of the largest specialized providers of venture capital within life sciences in Europe. Oncos is headquartered in Helsinki, Finland and has an office in Switzerland. For more information about Oncos, please visit http://www.oncos.com.

 


'/>"/>
SOURCE Oncos Therapeutics Ltd
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. OncoSec Medical Updates Analysis of Interim Data for Phase II Study of ImmunoPulse in Metastatic Melanoma Patients
2. OncoSec Medical to Present at the HemOnc Today Melanoma and Cutaneous Malignancies Meeting in New York
3. OncoSec Medical to Present at the 25th Annual Roth Conference
4. OncoSec Medical Promotes Veronica Vallejo to Chief Financial Officer
5. OncoSec Medical to Present at the 15th Annual BIO CEO & Investor Conference
6. OncoSec Medical to Present at Noble Financial Capital Markets Ninth Annual Equity Conference on January 22
7. OncoSec Medical Announces $7.2 Million Public Offering
8. OncoSec Medical to Present Data at DNA Vaccines 2012 Conference
9. OncoSec Medical Reports Positive Preliminary Efficacy Results from Phase II Study of ImmunoPulse in Metastatic Melanoma Patients
10. OncoSec Medical Reports Positive Interim Efficacy Results from Phase IV Study of NeoPulse in Skin Cancer Patients
11. OncoSec to Present at Upcoming Healthcare and Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... -- Story Highlights: , ... health care industry is causing providers to review operating ... offers a suite of solutions for health care providers ... optimization: labor resource analysis, revenue cycle optimization and physician ... and better economics ...
(Date:6/24/2016)... CAMBRIDGE, Mass. , June 24, 2016 /PRNewswire/ ... the Spaulding Rehabilitation Network,s Dean Center for ... of Physical Medicine and Rehabilitation, MIT Hacking Medicine, ... Center for Innovation, today announced the five finalists ... Hackathon for Lyme disease.  More than 100 scientists, ...
(Date:6/24/2016)... , June 24, 2016 Dehaier Medical Systems ... "Company"), which develops, markets and sells medical devices and ... , signed a strategic cooperation agreement with Hongyuan Supply ... Supply Chain") on June 20, 2016, to develop Dehaier,s ... strategic cooperation agreement, Dehaier will leverage Hongyuan Supply Chain,s ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements owned by ... to enhance the health of felines. The formula is all-natural and is made from ... the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus Root Extract ...
(Date:6/25/2016)... ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library on June ... , brings up a new, often overlooked aspect of head lice: the parasite’s ability to ... is not a common occurrence, but a necessary one in the event that lice have ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary ... Work award to iHire in recognition of their exemplary accomplishments in worksite health promotion. ... Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... Marcy was in a crisis. Her ... would lash out at his family verbally and physically. , “When something upset him, he ... he would use it. He would throw rocks at my other children and say he ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway ... call for a minimum wage raise to $12 an hour by 2020 and then adjusting ... restore the lost value of the minimum wage, assure the wage floor does not erode ...
Breaking Medicine News(10 mins):